Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; IDH1 NP_005887.2:p.R132C; IDH1 NP_005887.2:p.R132G; IDH1 NP_005887.2:p.R132H; IDH1 NP_005887.2:p.R132L; IDH1 NP_005887.2:p.R132S; IDH1 NP_005887.2:p.R132V; IDH2 NP_002159.2:p.R140L; IDH2 NP_002 159.2:p.R140Q; IDH2 NP_002159.2:p.R140W; IDH2 NP_002159.2:p.R140X; IDH2 NP_002159.2:p.R172G; IDH2 NP_002159.2:p.R172K; IDH2 NP_002159.2:p.R172M; IDH2 NP_002159.2:p.R172S; IDH2 NP_002159.2:p.R172W; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Re fractory Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia Intervention: Drug: Olaparib Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Leukemia | Myelodysplastic Syndrome | Research